The Market for Bioengineered Protein Drugs
The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%.
Modified and engineered antibodies present the largest share of the total global market. In 2006, this sector held almost 56% of the global market. By the end of 2011 its share will drop slightly but not significantly to 54%.
Hormone protein drugs have the largest AAGR through the forecast period, averaging 5.1% through 2011 to reach $11.9 billion by 2011.
This report updates BCC's report Market for Bioengineered Protein Drugs and reviews the global markets for the different types of protein drugs as well as forecasts for trends and sales through 2011. Important research developments, regulatory trends and other factors influencing demand will be discussed.
Protein drugs, as the name suggests, are pharmaceuticals based on proteins or portions of proteins. Also referred to as biologics, protein drugs have become increasingly important over the past 5 years with the advent of high throughput screening and proteomics combined with the changing (some would say declining) health status of the developed countries, particularly the United States.
Technologies included in this report are: protein therapeutics, proteomics, bioengineered protein drugs, recombinant protein drugs, protein arrays, protein expression and protein purification, and protein chips.
Drugs included in this report are insulin, coagulants, interferons, cytokines, bioengineered antibodies, enzymes, hormones (particularly growth hormones), growth factors, interleukins and angiogenesis inhibitors.
Diseases for which protein drugs are particularly amenable and that will be discussed in this report include: hemophilia, diabetes, cancer, cystic fibrosis, hepatitis, psoriasis and congenital diseases.
SCOPE OF STUDY
This report contains:
- Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials
- Market trends and five-year forecasts with projections through 2011
- Examination of current technologies underlying the market and details the effects of new technologies on this market
- Profiles of the major companies involved in the production and modification of protein drugs.
- An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
METHODOLOGY AND SOURCES
This report uses a combination of direct and indirect sources. Direct sources include interviews and conversations with scientists, analysts and research consultants. Indirect sources include company news releases, governmental and nongovernmental agencies, scientific journals and the popular press.
Sales were gathered from the most recently available data and represent worldwide sales. In nearly all cases, this involved year-end 2005 sales. If these figures were not available, then the latest available figures were used.
In some cases, data was not available. In these cases estimates were made based on indirect data, such as patient populations, percentages treated with other drugs and average sales prices.
Estimates for future sales growth within individual markets depended upon: patent expirations, percentage of the market penetrated, generic competition, competing drug classes, the introduction of new drugs, demographic growth and shifts, recent study results, and other variables. In each case where a forecast is made, the most important factors are listed.
Sales are presented in millions of dollars, unless otherwise noted.
Gargi Talukder has a doctorate in Neuroscience from Stanford University and a law degree from the University of Chicago. She has over 10 years of experience in the biotechnology sector.
In 2002, drug companies sold nearly $33 billion in protein drugs, and they are projected to approach $40 billion in 2003.
Rising at an average annual growth rate (AAGR) of 12.2%, this market is expected to reach $71 billion in 2008.
Replacement proteins constitute the bulk of the market and will rise at an AAGR of 9.8% from $31.4 billion in 2003 to $50 billion in 2008.
Monoclonal antibodies and fusion proteins will rise from $8.5 billion in 2003 to $20.1 billion in 2008.
These products effectively strip market share from older, less effective therapies. Most notably, a number of monoclonal antibodies are in the last stages of clinical trials for the treatment of autoimmune disease and cancer and promise to be blockbuster products.